GSA Capital Partners LLP Purchases New Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

GSA Capital Partners LLP acquired a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,047 shares of the medical instruments supplier’s stock, valued at approximately $30,000.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after purchasing an additional 49,576 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in Harvard Bioscience during the 1st quarter valued at about $54,000. Assenagon Asset Management S.A. boosted its holdings in shares of Harvard Bioscience by 193.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after acquiring an additional 150,218 shares during the last quarter. Riverwater Partners LLC raised its holdings in shares of Harvard Bioscience by 13.7% during the second quarter. Riverwater Partners LLC now owns 105,977 shares of the medical instruments supplier’s stock valued at $302,000 after purchasing an additional 12,780 shares during the last quarter. Finally, Pasadena Private Wealth LLC lifted its position in Harvard Bioscience by 14.8% during the second quarter. Pasadena Private Wealth LLC now owns 198,039 shares of the medical instruments supplier’s stock valued at $564,000 after purchasing an additional 25,554 shares during the period. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience Trading Down 1.3 %

NASDAQ:HBIO opened at $2.24 on Tuesday. The company has a market cap of $97.71 million, a PE ratio of -6.79 and a beta of 1.31. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. The company has a 50 day simple moving average of $2.45 and a two-hundred day simple moving average of $2.82. Harvard Bioscience, Inc. has a 12 month low of $1.99 and a 12 month high of $5.56.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.